- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 26.02. | Accent halts solid tumor trial over adverse events, pivots to other lead cancer program | ||
| 25.02. | ARPA-H designates up to $144M for anti-aging medical research | ||
| 25.02. | After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate | ||
| 25.02. | GSK pays $950M in cash for Canadian biotech and its Winrevair-like blood pressure drug | ||
| 24.02. | Werewolf Therapeutics weighs sale or merger as cash reserves whimper | ||
| 24.02. | Harbour ships CTLA-4 asset to form new biotech in $1.1B biobucks deal | ||
| 24.02. | FDA freezes enrollment in MacroGenics cancer trial after patient death | ||
| 24.02. | Abcuro's KLRG1 antibody flunks phase 2/3 muscle disease study | ||
| 24.02. | GSK explores frontiers of siRNA with $1B deal for 2 drugs from Chinese biotech | ||
| 24.02. | Novo Nordisk's triple G candidate drives 20% weight loss in phase 2 trial in China | ||
| 24.02. | Protara sees 66% 6-month bladder cancer response rate, but drops to 33% at 12 months | ||
| 24.02. | Galapagos takes €228M hit from cell therapy wind-down but still has cash for dealmaking | ||
| 23.02. | 'The perfect partner': Astellas, Vir engage in $1.7B deal for masked prostate cancer bispecific | ||
| 23.02. | FDA illuminates new approval pathway for bespoke gene editing therapies | ||
| 23.02. | Angelini nocks an AI arrow with $120M Quiver Bioscience deal | ||
| 23.02. | Gossamer's stock sinks after phase 3 pulmonary arterial hypertension fail | ||
| 23.02. | Generate plans $425M IPO to bankroll antibody's phase 3 asthma trials | ||
| 23.02. | Gilead inks $7.8B Arcellx buyout to steer CAR-T into J&J showdown | ||
| 23.02. | Novo's CagriSema loses phase 3 battle with Lilly's Zepbound, knocking 15% off share price | ||
| 23.02. | MoonLake's phase 2 arthritis win kicks off pivotal year for IL-17 nanobody | ||
| 20.02. | Ionis scraps early candidate for Alzheimer's in people with Down syndrome | ||
| 20.02. | Biohaven charts comeback path after FDA blow, placing bets on obesity | ||
| 20.02. | Daiichi picks former Novartis CMO John Tsai to head up R&D | ||
| 20.02. | Candel glows brighter with $100M RTW royalty deal to fund prostate cancer drug's launch | ||
| 19.02. | Novartis winds down ph. 1 solid tumor program after lacking efficacy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.